Interaction between Ciprofloxacin and Prednisone
Major
Synergy
| ID | DDInter384 and DDInter1515 |
| Interaction |
Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.
abdominal distension
abdominal pain
abscess
Acidosis
acute pancreatitis
agoraphobia
alcohol consumption
allergic rhinitis
alopecia
Amnesia
More
|
| Management | Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon. |
| References | |
| Alternative for Ciprofloxacin |
J01R
S03A Neomycin (topical)
Chloramphenicol (ophthalmic)
Gentamicin (topical)
Neomycin
Polymyxin B
Tetracycline (topical)
More
|
| Alternative for Prednisone |
A07E
Cromoglicic acid
Betamethasone (topical)
Prednisolone (ophthalmic)
Beclomethasone dipropionate
Olsalazine
Beclomethasone dipropionate (nasal)
H02A
More
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.